The Cause, Aetiology and Physiopathology of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) and its Effective Treatment with Thermobalancing Therapy

Abstract

Introduction: Type-III chronic prostatitis (CP) is characterized by pelvic pain, sexual dysfunction and urinary symptoms in the absence of infection. It is also known as chronic pelvic pain syndrome (CPPS) This study discusses the cause of CP/CPPS, the understanding of which can help to find effective therapy. Materials: An observational clinical trial, before and 6 months after treatment with Thermobalancing therapy (TT) and Dr Allen’s therapeutic device (DATD), which uses natural body energy, has been used. The treatment group-45 patients with CP/CPPS, who received DATD, and the control group-45 men with CP/CPPS, who not. Methods: The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) include examination of pain score and quality of life (QoL), ultrasound-prostate volume (PVmL), uroflowmetry-maximum urine flow rate (Qmax). Results: Compared to control, significant improvements from baseline to endpoint were seen: pain score, 10.38 to 3.58 against 10.49 to 9.71, (P<0.001); QoL index 8.11 to 2.98; against 8.47 to 8.33 (P<0.001); PVmL 31.75 ± 7.01 to 27.07 ± 4.52 against 30.77 ± 6.44 to 31.58 ± 7.14 (P<0.001); QmaxmL/sec, 11.93 ± 4.34 to 16.45 ± 3.50 against 12.59 ± 3.57 to 12.20 ± 2.54 (P<0.001). Conclusions: Vascular changes, namely pathological activity of capillaries, in the prostate tissue cause CP/ CPPS. The focus of hypothermia combined with spontaneous expansion of capillaries create the pressure in the prostate tissue and, consequently, the CP/CPPS symptoms. DATD, by accumulation of emitted body heat and spreading this safe energy to the prostate in men with CP/CPPS, relieves pain and other symptoms effectively.